Johnson & Johnson (JNJ)
NYSE: JNJ · Real-Time Price · USD
248.56
+0.13 (0.05%)
At close: Mar 2, 2026, 4:00 PM EST
249.05
+0.49 (0.20%)
After-hours: Mar 2, 2026, 7:56 PM EST
Johnson & Johnson Revenue
Johnson & Johnson had revenue of $24.28B in the quarter ending December 31, 2025, with 10.90% growth. This brings the company's revenue in the last twelve months to $94.19B, up 5.44% year-over-year. In the year 2025, Johnson & Johnson had annual revenue of $94.19B with 6.05% growth.
Revenue (ttm)
$94.19B
Revenue Growth
+5.44%
P/S Ratio
6.36
Revenue / Employee
$681,570
Employees
138,200
Market Cap
599.00B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 28, 2025 | 94.19B | 5.37B | 6.05% |
| Dec 29, 2024 | 88.82B | 3.66B | 4.30% |
| Dec 31, 2023 | 85.16B | 5.17B | 6.46% |
| Jan 1, 2023 | 79.99B | 1.25B | 1.59% |
| Jan 2, 2022 | 78.74B | -3.84B | -4.65% |
| Jan 3, 2021 | 82.58B | 525.00M | 0.64% |
| Dec 29, 2019 | 82.06B | 478.00M | 0.59% |
| Dec 30, 2018 | 81.58B | 5.13B | 6.71% |
| Dec 31, 2017 | 76.45B | 4.56B | 6.34% |
| Jan 1, 2017 | 71.89B | 1.82B | 2.59% |
| Jan 3, 2016 | 70.07B | -4.26B | -5.73% |
| Dec 28, 2014 | 74.33B | 3.02B | 4.23% |
| Dec 29, 2013 | 71.31B | 4.09B | 6.08% |
| Dec 30, 2012 | 67.22B | 2.19B | 3.37% |
| Jan 1, 2012 | 65.03B | 3.44B | 5.59% |
| Jan 2, 2011 | 61.59B | -310.00M | -0.50% |
| Jan 3, 2010 | 61.90B | -1.85B | -2.90% |
| Dec 28, 2008 | 63.75B | 2.65B | 4.34% |
| Dec 30, 2007 | 61.10B | 7.77B | 14.57% |
| Dec 31, 2006 | 53.32B | 2.81B | 5.56% |
| Jan 1, 2006 | 50.51B | 3.17B | 6.69% |
| Jan 2, 2005 | 47.35B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Eli Lilly and Company | 65.18B |
| Merck & Co. | 65.01B |
| Pfizer | 62.58B |
| AbbVie | 61.16B |
| AstraZeneca | 58.74B |
| Novartis AG | 56.67B |
| Novo Nordisk | 48.59B |
| Bristol-Myers Squibb Company | 48.19B |
JNJ News
- 8 hours ago - Johnson & Johnson to Host Investor Conference Call on First-Quarter Results - Business Wire
- 3 days ago - Best Dividend Aristocrats For March 2026 - Seeking Alpha
- 4 days ago - 2 Dividend Kings That Could Easily Keep The Growth Streak Alive - Seeking Alpha
- 4 days ago - Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer - PRNewsWire
- 6 days ago - Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA) - PRNewsWire
- 7 days ago - Does JNJ Stock Still Offer Value? - Forbes
- 7 days ago - Bayer files lawsuit against Johnson & Johnson, Janssen Biotech - Reuters
- 7 days ago - Bayer Alleges J&J's Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J's ERLEADA - Business Wire